# A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Source: https://onco.cc/trials/nct04819100/  
OnCo record `nct04819100` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Selpercatinib in non-small-cell lung cancer, run by Eli Lilly and Company, active and no longer recruiting.

## Summary

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) is a phase 3 interventional study registered as NCT04819100 by Eli Lilly and Company, with 152 participants enrolled, started 2021-12-20 and due to reach its primary completion in 2026-01-12. Interventions recorded: Selpercatinib and Placebo.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04819100
- Phase: 3
- Setting: LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
- Sponsor: Eli Lilly and Company
- Enrolled: 152

## Sources

- ClinicalTrials.gov NCT04819100: https://clinicaltrials.gov/study/NCT04819100

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Selpercatinib](https://onco.cc/drugs/selpercatinib/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)

---
JSON: https://onco.cc/api/v1/entities/nct04819100.json